drugset
drugset / Trial / NCT06065813

Neoadjuvant Triprizumab and Radiotherapy in Operable Patients With Stage IIA-IIIA Non-small Cell Lung Cancer

NCT06065813 ↗

Phase 2 Unknown 20 enrolled Northern Jiangsu People's Hospital Shanghai Junshi Bioscience Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment

Summary

Neoadjuvant Triprizumab and Radiotherapy in Operable Patients With Stage IIA-IIIA Non-small Cell Lung Cancer

Timeline

Start
2022-08-08
Primary completion
2026-05-30
Completion
2026-05-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Toripalimab Monoclonal antibody 200 mg Intravenous

Indications

non-small cell lung carcinoma